Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
December 17, 2018 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
November 06, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with...
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
October 03, 2018 09:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
June 21, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and...
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
June 06, 2018 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND – – Appointment brings regulatory experience to the Board of...
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
May 24, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Live audio presentation and webcast on Wednesday, June 6th at 9:00 a.m. EDT - Norwood, MA, May 24, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
May 22, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing — — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
May 15, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented - Norwood, MA, May 15,...
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
May 10, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Company continues to make consistent progress in the clinical development programs of lenabasum, in rare, chronic and serious inflammatory and fibrotic diseases – Norwood, MA, May 10, 2018 ...